Arthritis & Rheumatology· 2026Q1
Hypogammaglobulinemia in Patients With Inflammatory Rheumatic Diseases Treated With IL-6 Receptor Inhibitors: A Retrospective Comparative Cohort Study.
- 0citations
- Q1SCImago
- 2026year
Short summary
Patients treated with IL-6 receptor inhibitors (IL-6Ri) for inflammatory rheumatic diseases showed lower post-treatment IgG and IgA levels and higher hypogammaglobulinemia rates compared to those on TNF inhibitors (TNFi).
AI-generated from the title and abstract; the full text is not read.
Key points
- IL-6Ri treatment in rheumatic diseases is associated with lower post-treatment IgG and IgA levels compared to TNFi.
- Patients on IL-6Ri have a higher prevalence of hypogammaglobulinemia post-treatment.
- Baseline hypogammaglobulinemia and age ≥65 years are significant risk factors for developing post-treatment hypogammaglobulinemia.
- The study suggests assessing and potentially monitoring immunoglobulin levels in IL-6Ri users.
AI-generated from the title and abstract; the full text is not read.
Abstract
This poster presents the results of a retrospective comparative cohort study evaluating hypogammaglobulinemia and serum immunoglobulin levels in patients with inflammatory rheumatic diseases treated with interleukin-6 receptor inhibitors (IL-6Ri) compared with tumor necrosis factor inhibitors (TNFi). Patients treated with IL-6Ri had lower post-treatment IgG and IgA levels and a higher prevalence of hypogammaglobulinemia than those treated with TNFi. In multivariable analysis, baseline hypogammaglobulinemia and age ≥65 years were the main factors associated with post-treatment hypogammaglobulinemia. The findings highlight the importance of assessing baseline immunoglobulin levels and considering immunoglobulin monitoring in patients treated with IL-6 receptor inhibitors, particularly those with risk factors for hypogammaglobulinemia. This poster was presented at the American College of Rheumatology (ACR) Convergence 2026.
The authors' abstract, as published at the source. Arthritis & Rheumatology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Rheumatology
RheumatologyMedicine